News
ALPN
--
0.00%
--
Alpine Immune Sciences to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Alpine Immune Sciences to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Business Wire · 09/15 20:05
Alpine Immune Sciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference
Alpine Immune Sciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference
Business Wire · 09/08 20:05
New Strong Sell Stocks for September 8th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.
Zacks · 09/08 13:57
Benzinga's Top Upgrades, Downgrades For August 26, 2020
Upgrades * Evercore ISI Group upgraded the previous rating for The Hain Celestial Group Inc (NASDAQ: HAIN) from In-Line to Outperform. In the fourth quarter, Hain Celestial Group showed an EPS of $0.32, compared to $0.21 from the year-ago quarter. The stock has a 52-week-high of $34.53 and a 52-week-low
Benzinga · 08/26 13:42
Alpine Immune Sciences Q2 EPS $(0.53) Up From $(0.64) YoY, Sales $688.00K Up From $567.00K YoY
Alpine Immune Sciences (NASDAQ:ALPN) reported quarterly losses of $(0.53) per share. This is a 17.19 percent increase over losses of $(0.64) per share from the same period last year. The company reported $688.00
Benzinga · 08/11 20:19
Alpine Immune Sciences to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
Alpine Immune Sciences to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
Business Wire · 08/05 20:05
Alpine Immune Sciences to Report Second Quarter 2020 Financial Results and Provide Corporate Update
Alpine Immune Sciences to Report Second Quarter 2020 Financial Results and Provide Corporate Update
Business Wire · 08/04 20:05
Alpine Immune Sciences secures equity capital of $60M
Seeking Alpha · 07/24 13:46
Alpine Immune Sciences Reports $60M Private Placement
Benzinga · 07/24 13:15
Alpine Immune Sciences Announces $60 Million Private Placement
Alpine Immune Sciences Announces $60 Million Private Placement
Business Wire · 07/24 13:15
Mixed shelf roundup - healthcare
The following medical companies have filed for mixed shelf offerings: Ardelyx (ARDX -4.5%): $250M. Vaxart (VXRT +1.7%): $100M. Alpine Immune Sciences (ALPN
seekingalpha · 07/09 21:34
Alpine Immune Sciences S-3 Shows Registration For $60M Mixed Securities Shelf Offering
Benzinga · 07/08 21:16
The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio
Zacks · 07/08 14:05
Alpine Immune Sciences, Inc. (ALPN) Shares March Higher, Can It Continue?
Zacks · 07/08 12:35
Alpine Begins Dosing in Phase I Study for Advanced Malignancies
Alpine (ALPN) doses the first patient in the phase I NEON-1 study evaluating its pipeline candidate ALPN-202 for treating patients with advanced malignancies.
Zacks · 06/25 16:09
Alpine Immune Sciences doses first patient in Phase 1 study of ALPN-202
Seeking Alpha - Article · 06/24 14:21
IBN, EDIT among premarket losers
Seeking Alpha - Article · 06/24 12:15
Alpine Immune Sciences Announces First Patient Dosed In NEON-1 Phase 1 Trial Of ALPN-202 In Patients With Advanced Malignancies
- ALPN-202 is a first-in-class conditional CD28 costimulator and dual checkpoint inhibitor - SEATTLE--(BUSINESS WIRE)-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused
ALPN-202 is a first-in-class conditional CD28 costimulator and dual checkpoint inhibitor - SEATTLE--(BUSINESS WIRE)-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused · 06/24 12:01
Alpine Immune Sciences Announces First Patient Dosed in NEON-1 Phase 1 Trial of ALPN-202 in Patients with Advanced Malignancies
Alpine Immune Sciences Announces First Patient Dosed in NEON-1 Phase 1 Trial of ALPN-202 in Patients with Advanced Malignancies
Business Wire · 06/24 12:00
NIO, SPCE among premarket gainers
Seeking Alpha - Article · 06/22 12:21